BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg. 2003;138:951-955; discussion 951-955. [PMID: 12963650 DOI: 10.1001/archsurg.138.9.951] [Cited by in Crossref: 122] [Cited by in F6Publishing: 107] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Abdallah R, Taly V, Zhao S, Pietrasz D, Bachet JB, Basile D, Mas L, Zaanan A, Laurent-Puig P, Taieb J. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. Cancer Treat Rev 2020;87:102028. [PMID: 32485509 DOI: 10.1016/j.ctrv.2020.102028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Ujiki MB, Talamonti MS. Guidelines for the Surgical Management of Pancreatic Adenocarcinoma. Seminars in Oncology 2007;34:311-20. [DOI: 10.1053/j.seminoncol.2007.05.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
3 Yamashita S, Passot G, Aloia TA, Chun YS, Javle M, Lee JE, Vauthey JN, Conrad C. Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer. Br J Surg 2017;104:267-77. [PMID: 28052308 DOI: 10.1002/bjs.10415] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
4 Kim YJ, Koh HK, Chie EK, Oh DY, Bang YJ, Nam EM, Kim K. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy. Int J Clin Oncol 2017;22:1069-75. [PMID: 28477059 DOI: 10.1007/s10147-017-1129-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Slaar A, Eshuis WJ, van der Gaag NA, Nio CY, Busch ORC, van Gulik TM, Reitsma JB, Gouma DJ. Predicting Distant Metastasis in Patients With Suspected Pancreatic and Periampullary Tumors for Selective Use of Staging Laparoscopy. World J Surg 2011;35:2528-34. [DOI: 10.1007/s00268-011-1204-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
6 Yang GY, Malik NK, Chandrasekhar R, Ma WW, Flaherty L, Iyer R, Kuvshinoff B, Gibbs J, Wilding G, Warren G, May KS. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer. J Gastrointest Oncol 2013;4:361-9. [PMID: 24294507 DOI: 10.3978/j.issn.2078-6891.2013.045] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
7 Huang Y, Xu Y, Bi Y, Xu M, Lu J, Wang T, Li M, Chen Y, Liu Y, Huang F, Xu B, Zhang J, Wang W, Ning G. Relationship between CA 19-9 levels and glucose regulation in a middle-aged and elderly Chinese population: CA 19-9 levels and glucose regulation. Journal of Diabetes 2012;4:147-52. [DOI: 10.1111/j.1753-0407.2011.00179.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
8 Satoi S, Yanagimoto H, Toyokawa H, Inoue K, Wada K, Yamamoto T, Hirooka S, Yamaki S, Yui R, Mergental H. Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer. Pancreas. 2011;40:426-432. [PMID: 21206325 DOI: 10.1097/mpa.0b013e3182056b1c] [Cited by in Crossref: 35] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
9 Lin JP, Lin JX, Ma YB, Xie JW, Yan S, Wang JB, Lu J, Chen QY, Ma XF, Cao LL, Lin M, Tu RH, Zheng CH, Li P, Huang CM. Prognostic significance of pre- and post-operative tumour markers for patients with gastric cancer. Br J Cancer 2020;123:418-25. [PMID: 32451469 DOI: 10.1038/s41416-020-0901-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
10 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.issn.2078-6891.2011.021] [Cited by in F6Publishing: 220] [Reference Citation Analysis]
11 De Rosa A, Cameron IC, Gomez D. Indications for staging laparoscopy in pancreatic cancer. HPB (Oxford). 2016;18:13-20. [PMID: 26776846 DOI: 10.1016/j.hpb.2015.10.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
12 Labarca-Acosta M, Reyna-Villasmil E, Aragón-Charris J, Santos-Bolívar J. [Pancreatic adenocarcinoma during pregnancy]. Cir Esp 2015;93:479-81. [PMID: 24120255 DOI: 10.1016/j.ciresp.2013.04.017] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Smith RA, Bosonnet L, Ghaneh P, Sutton R, Evans J, Healey P, Garvey C, Hughes M, Raraty M, Campbell F, Neoptolemos JP. The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery 2008;143:658-66. [PMID: 18436014 DOI: 10.1016/j.surg.2007.12.014] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 4.5] [Reference Citation Analysis]
14 Bouvet M. Tumor markers for pancreatic cancer: what happens when preoperative CA 19-9 is undetectable? Ann Surg Oncol 2004;11:637-8. [PMID: 15197009 DOI: 10.1245/ASO.2004.05.908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Bold RJ. Re: CA 19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and preoperative therapy. Ann Surg Oncol 2013;20:2108-10. [PMID: 23563959 DOI: 10.1245/s10434-012-2820-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
16 Maulat C, Canivet C, Touraine C, Gourgou S, Napoleon B, Palazzo L, Flori N, Piessen G, Guibert P, Truant S, Assenat E, Buscail L, Bournet B, Muscari F, The Bacap Consortium. A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score. Cancers (Basel) 2020;12:E783. [PMID: 32218346 DOI: 10.3390/cancers12040783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Luo G, Xiao Z, Long J, Liu Z, Liu L, Liu C, Xu J, Ni Q, Yu X. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. J Gastrointest Surg. 2013;17:2092-2098. [PMID: 24146342 DOI: 10.1007/s11605-013-2389-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
18 Brown KM, Siripurapu V, Davidson M, Cohen SJ, Konski A, Watson JC, Li T, Ciocca V, Cooper H, Hoffman JP. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg. 2008;195:318-321. [PMID: 18308038 DOI: 10.1016/j.amjsurg.2007.12.017] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 4.6] [Reference Citation Analysis]
19 Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol. 2011;2:88-100. [PMID: 22693400 DOI: 10.1007/s13193-011-0042-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 107] [Article Influence: 11.1] [Reference Citation Analysis]
20 Brown EG, Canter RJ, Bold RJ. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma. J Surg Oncol. 2015;111:293-298. [PMID: 25330934 DOI: 10.1002/jso.23812] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
21 Kanda M, Fujii T, Takami H, Suenaga M, Inokawa Y, Yamada S, Nakayama G, Sugimoto H, Koike M, Nomoto S. The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today. 2014;44:1692-1701. [PMID: 24114022 DOI: 10.1007/s00595-013-0752-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
22 Sakaguchi T, Satoi S, Hashimoto D, Yamamoto T, Yamaki S, Hirooka S, Ishida M, Ikeura T, Inoue K, Sekimoto M. A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 2021. [PMID: 34314568 DOI: 10.1002/jhbp.1026] [Reference Citation Analysis]
23 Vasiliades G, Kopanakis N, Vasiloglou M, Zografos G, Margaris H, Masselou K, Kokosi E, Liakakos T. Role of the hematopoietic cytokines SCF, IL-3, GM-CSF and M-CSF in the diagnosis of pancreatic and ampullary cancer. Int J Biol Markers 2012;27:e186-94. [PMID: 22865301 DOI: 10.5301/JBM.2012.9348] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
24 Duraker N, Hot S, Polat Y, Höbek A, Gençler N, Urhan N. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol. 2007;95:142-147. [PMID: 17262731 DOI: 10.1002/jso.20604] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 5.5] [Reference Citation Analysis]
25 Müller SA, Hartel M, Mehrabi A, Welsch T, Martin DJ, Hinz U, Schmied BM, Büchler MW. Vascular resection in pancreatic cancer surgery: survival determinants. J Gastrointest Surg. 2009;13:784-792. [PMID: 19137380 DOI: 10.1007/s11605-008-0791-5] [Cited by in Crossref: 122] [Cited by in F6Publishing: 110] [Article Influence: 9.4] [Reference Citation Analysis]
26 Fritz S, Hackert T, Hinz U, Hartwig W, Büchler MW, Werner J. Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg. 2011;98:104-110. [PMID: 20949535 DOI: 10.1002/bjs.7280] [Cited by in Crossref: 103] [Cited by in F6Publishing: 96] [Article Influence: 8.6] [Reference Citation Analysis]
27 Liu X, Fu Y, Chen Q, Wu J, Gao W, Jiang K, Miao Y, Wei J. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer. BMC Gastroenterol 2018;18:168. [PMID: 30400836 DOI: 10.1186/s12876-018-0891-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
28 Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA, Samra JS, Gill AJ, Kench JG, Merrett ND, Das A, Musgrove EA, Sutherland RL, Biankin AV;  NSW Pancreatic Cancer Network. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713-1722. [PMID: 22241899 DOI: 10.1093/annonc/mdr561] [Cited by in Crossref: 148] [Cited by in F6Publishing: 135] [Article Influence: 14.8] [Reference Citation Analysis]
29 Tsen A, Barbara M, Rosenkranz L. Dilemma of elevated CA 19-9 in biliary pathology. Pancreatology. 2018;18:862-867. [PMID: 30249386 DOI: 10.1016/j.pan.2018.09.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
30 Chen S, Feng XY, Li YF, Zhao BW, Zhou ZW, Chen YB. The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy. J Surg Oncol. 2013;107:641-645. [PMID: 23297055 DOI: 10.1002/jso.23300] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
31 Pietrasz D, Marthey L, Wagner M, Blanc JF, Laurent C, Turrini O, Raoul JL, Terrebonne E, Hentic O, Trouilloud I, Coriat R, Regenet N, Innominato P, Taieb J, Cunha AS, Bachet JB. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort. Ann Surg Oncol. 2015;22 Suppl 3:S1196-S1205. [PMID: 26271395 DOI: 10.1245/s10434-015-4783-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 7.1] [Reference Citation Analysis]
32 Stefanidis D, Grove K, Schwesinger W, Thomas C. The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Annals of Oncology 2006;17:189-99. [DOI: 10.1093/annonc/mdj013] [Cited by in Crossref: 76] [Cited by in F6Publishing: 62] [Article Influence: 4.8] [Reference Citation Analysis]
33 Zhou G, Niu L, Chiu D, He L, Xu K. Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF-α and TSGF after cryosurgery in pancreatic cancer patients. Biotechnol Lett. 2012;34:1235-1241. [PMID: 22456901 DOI: 10.1007/s10529-012-0908-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
34 Huang Z, Liu F. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour Biol. 2014;35:7459-7465. [PMID: 24789274 DOI: 10.1007/s13277-014-1995-9] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 7.5] [Reference Citation Analysis]
35 Katz MH, Savides TJ, Moossa AR, Bouvet M. An evidence-based approach to the diagnosis and staging of pancreatic cancer. Pancreatology. 2005;5:576-590. [PMID: 16110256 DOI: 10.1159/000087500] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
36 Mehtsun WT, Hashimoto DA, Ferrone CR. Status of 5-Year Survivors of the Whipple Procedure for Pancreatic Adenocarcinoma. Advances in Surgery 2019;53:253-69. [DOI: 10.1016/j.yasu.2019.04.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Luo G, Jin K, Guo M, Cheng H, Liu Z, Xiao Z, Lu Y, Long J, Liu L, Xu J, Liu C, Gao Y, Ni Q, Yu X. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. Oncol Lett 2017;13:881-6. [PMID: 28356973 DOI: 10.3892/ol.2016.5501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
38 Navarro S, Vaquero E, Maurel J, Bombí JA, De Juan C, Feliu J, Fernández Cruz L, Ginés À, Girela E, Rodríguez R, Sabater L. Recomendaciones para el diagnóstico, la estadificación y el tratamiento del cáncer de páncreas (parte I). Medicina Clínica 2010;134:643-55. [DOI: 10.1016/j.medcli.2009.12.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5:845-856. [PMID: 16239904 DOI: 10.1038/nrc1739] [Cited by in Crossref: 1100] [Cited by in F6Publishing: 977] [Article Influence: 68.8] [Reference Citation Analysis]
40 Pietrasz D, Turrini O, Vendrely V, Simon J, Hentic O, Coriat R, Portales F, Le Roy B, Taieb J, Regenet N, Goere D, Artru P, Vaillant J, Huguet F, Laurent C, Sauvanet A, Delpero J, Bachet JB, Sa Cunha A. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. Ann Surg Oncol 2019;26:109-17. [DOI: 10.1245/s10434-018-6931-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
41 Nishio K, Kimura K, Amano R, Yamazoe S, Ohrira G, Nakata B, Hirakawa K, Ohira M. Preoperative predictors for early recurrence of resectable pancreatic cancer. World J Surg Oncol 2017;15:16. [PMID: 28069033 DOI: 10.1186/s12957-016-1078-z] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
42 Zhang S, Wang YM, Sun CD, Lu Y, Wu LQ. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol 2008; 14(23): 3750-3753 [PMID: 18595144 DOI: 10.3748/wjg.14.3750] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
43 Yamada Y, Mori H, Matsumoto S, Kiyosue H, Hori Y, Hongo N. Pancreatic adenocarcinoma versus chronic pancreatitis: differentiation with triple-phase helical CT. Abdom Imaging. 2010;35:163-171. [PMID: 19771464 DOI: 10.1007/s00261-009-9579-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
44 Molina V, Visa L, Conill C, Navarro S, Escudero JM, Auge JM, Filella X, Lopez-Boado MA, Ferrer J, Fernandez-Cruz L, Molina R. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumour Biol. 2012;33:799-807. [PMID: 22203495 DOI: 10.1007/s13277-011-0297-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
45 Maithel SK, Maloney S, Winston C, Gönen M, D’Angelica MI, Dematteo RP, Jarnagin WR, Brennan MF, Allen PJ. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2008;15:3512-3520. [PMID: 18781364 DOI: 10.1245/s10434-008-0134-5] [Cited by in Crossref: 130] [Cited by in F6Publishing: 107] [Article Influence: 9.3] [Reference Citation Analysis]
46 Liu Z, Li L, Liu X, Zhang D. Comparative Analysis of Tumor Markers and Evaluation of Their Predictive Value in Patients with Colorectal Cancer. Onkologie 2012;35:108-13. [DOI: 10.1159/000336816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
47 Hoffman JP. Status of Neoadjuvant Therapy for Resectable Pancreatic Cancer. Surgical Oncology Clinics of North America 2010;19:411-8. [DOI: 10.1016/j.soc.2009.11.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
48 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.1002/ijc.20037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
49 Barthet M, Moutardier V, Marciano S. [Adenocarcinomas of the pancreas: how best to evaluate resectability?]. Gastroenterol Clin Biol 2007;31:216-21. [PMID: 17347637 DOI: 10.1016/s0399-8320(07)89361-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
50 Chen T, Zhang MG, Xu HX, Wang WQ, Liu L, Yu XJ. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma. Medicine (Baltimore). 2015;94:e751. [PMID: 25984661 DOI: 10.1097/md.0000000000000751] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
51 Kim BH, Kim E, Kim K, Jang J, Kim SW, Oh D, Chie EK. The impact of perioperative CA19-9 change on the survival and recurrence patterns after adjuvant chemoradiotherapy in resectable extrahepatic cholangiocarcinoma. J Surg Oncol 2018;117:380-8. [DOI: 10.1002/jso.24856] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
52 Ong SL, Garcea G, Thomasset SC, Mann CD, Neal CP, Abu Amara M, Dennison AR, Berry DP. Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma. J Gastrointest Surg 2008;12:1068-73. [PMID: 18043987 DOI: 10.1007/s11605-007-0422-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
53 Xie ZB, Gu JC, Zhang YF, Yao L, Jin C, Jiang YJ, Li J, Yang F, Zou CF, Fu DL. Portal vein resection and reconstruction with artificial blood vessels is safe and feasible for pancreatic ductal adenocarcinoma patients with portal vein involvement: Chinese center experience. Oncotarget 2017;8:77883-96. [PMID: 29100433 DOI: 10.18632/oncotarget.20847] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
54 Lu LH, Zhang YF, Wei W, Shi M, Guo RP. Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients. J Gastrointest Surg. 2017;21:2025-2032. [PMID: 28840443 DOI: 10.1007/s11605-017-3528-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
55 Liu MP, Guo XZ, Xu JH, Wang D, Li HY, Cui ZM, Zhao JJ, Ren LN. New tumor-associated antigen SC6 in pancreatic cancer. World J Gastroenterol 2005;11:7671-5. [PMID: 16437697 DOI: 10.3748/wjg.v11.i48.7671] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
56 Hoskovec D, Varga J, Konečná E, Antos F. Levels of CEA and Ca 19 - 9 in the sera and peritoneal cavity in patients with gastric and pancreatic cancers. Acta Cir Bras. 2012;27:410-416. [PMID: 22666759 DOI: 10.1590/S0102-86502012000600009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
57 Hashimoto Y, Ajiki T, Yanagimoto H, Tsugawa D, Shinozaki K, Toyama H, Kido M, Fukumoto T. Risk factors for occult metastasis detected by inflammation-based prognostic scores and tumor markers in biliary tract cancer. World J Clin Cases 2021; 9(32): 9770-9782 [PMID: 34877316 DOI: 10.12998/wjcc.v9.i32.9770] [Reference Citation Analysis]
58 Liu L, Xu H, Wang W, Wu C, Chen Y, Yang J, Cen P, Xu J, Liu C, Long J. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer. 2015;136:2216-2227. [PMID: 25273947 DOI: 10.1002/ijc.29242] [Cited by in Crossref: 44] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
59 Park JK, Paik WH, Ryu JK, Kim YT, Kim YJ, Kim J, Song BJ, Park JM, Yoon YB. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution. PLoS One. 2013;8:e78977. [PMID: 24250822 DOI: 10.1371/journal.pone.0078977] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
60 Ma W, Li W, Wang J, Wu R, Liu C, Feng F, Jiang X. The Clinical Role of Preoperative Serum CA19-9 and Carcinoembryonic Antigen (CEA) Levels in Evaluating the Resectability of Advanced Gallbladder Cancer. Med Sci Monit 2020;26:e925017. [PMID: 32950997 DOI: 10.12659/MSM.925017] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Zheng Z, Wang X, Lu X, Huang Y, Chi P. Prognostic significance of carcinoembryonic antigen combined with carbohydrate antigen 19-9 following neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Colorectal Dis 2021. [PMID: 33900006 DOI: 10.1111/codi.15694] [Reference Citation Analysis]
62 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.ssn.2078-6891.2011.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Arigami T, Mori S, Ueno S, Shinchi H, Takao S, Natsugoe S. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma. Pancreatology 2016;16:1051-6. [DOI: 10.1016/j.pan.2016.09.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
64 Brown KM. Multidisciplinary approach to tumors of the pancreas and biliary tree. Surg Clin North Am. 2009;89:115-131, ix. [PMID: 19186234 DOI: 10.1016/j.suc.2008.09.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
65 Jiang JT, Wu CP, Deng HF, Lu MY, Wu J, Zhang HY, Sun WH, Ji M. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. World J Gastroenterol 2004; 10(11): 1675-1677 [PMID: 15162550 DOI: 10.3748/wjg.v10.i11.1675] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
66 Lennon AM, Goggins M. Diagnostic and Therapeutic Response Markers. Pancreatic Cancer. New York: Springer; 2010. pp. 675-701. [DOI: 10.1007/978-0-387-77498-5_28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
67 Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Sasaki K, Furukawa H, Matsunaga K, Maeda A. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16:977-985. [PMID: 22411488 DOI: 10.1007/s11605-012-1859-9] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 7.2] [Reference Citation Analysis]
68 Pandiaraja J, Viswanathan S, Antomy TB, Thirumuruganand S, Kumaresan DS. The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of Pancreas. J Clin Diagn Res 2016;10:PC06-9. [PMID: 27134925 DOI: 10.7860/JCDR/2016/17106.7398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
69 Parsons CM, Sutcliffe JL, Bold RJ. Preoperative evaluation of pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg. 2008;15:429-435. [PMID: 18670846 DOI: 10.1007/s00534-007-1240-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
70 Zhang D, Hou W, Liu F, Yin J, Lu W, Li M, Zheng T, Lu F, Bao Y, Jia W. Metformin reduces serum CA199 levels in type 2 diabetes Chinese patients with time-effect and gender difference. Diabetes Technol Ther. 2015;17:72-79. [PMID: 25548963 DOI: 10.1089/dia.2014.0176] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
71 Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897-902. [PMID: 16782929 DOI: 10.1200/JCO.2005.05.3934] [Cited by in Crossref: 320] [Cited by in F6Publishing: 152] [Article Influence: 20.0] [Reference Citation Analysis]
72 Trifunovic J, Muzikravic L, Prvulovic M, Salma S, Nikolin B, Kukic B. Evaluation of imaging techniques and ca 19-9 in differential diagnosis of carcinoma and other focal lesions of pancreas. Arch Oncol 2004;12:104-8. [DOI: 10.2298/aoo0402104t] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
73 Xu HX, Chen T, Wang WQ, Wu CT, Liu C, Long J, Xu J, Zhang YJ, Chen RH, Liu L, Yu XJ. Metabolic tumour burden assessed by ¹⁸F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging 2014;41:1093-102. [PMID: 24522797 DOI: 10.1007/s00259-014-2688-8] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
74 Connor S, Bosonnet L, Alexakis N, Raraty M, Ghaneh P, Sutton R, Neoptolemos J. Serum CA19-9 Measurement Increases the Effectiveness of Staging Laparoscopy in Patients with Suspected Pancreatic Malignancy. Dig Surg 2005;22:80-5. [DOI: 10.1159/000085297] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
75 Gong Y, Zhang L, He T, Ding J, Zhang H, Chen G, Zhang D, Wu Z, Chen Q, Fan H. Pancreaticoduodenectomy combined with vascular resection and reconstruction for patients with locally advanced pancreatic cancer: a multicenter, retrospective analysis. PLoS One. 2013;8:e70340. [PMID: 23936411 DOI: 10.1371/journal.pone.0070340] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
76 Lévy P. Adénocarcinome du pancréas : le dosage du CA 19-9 a-t-il un intérêt ? La Presse Médicale 2008;37:88-94. [DOI: 10.1016/j.lpm.2007.05.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
77 Wang W, Liu W, Zhang N, He X. Preoperative platelet-lymphocyte ratio is an independent prognostic factor in ampullary carcinoma following pancreaticoduodenectomy. Oncol Lett 2018;16:4879-88. [PMID: 30250554 DOI: 10.3892/ol.2018.9285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
78 Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, Yanaga K. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. J Hepatobiliary Pancreat Surg. 2007;14:539-544. [PMID: 18040617 DOI: 10.1007/s00534-006-1184-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.9] [Reference Citation Analysis]
79 Dong Q, Yang XH, Zhang Y, Jing W, Zheng LQ, Liu YP, Qu XJ. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study. World J Surg Oncol. 2014;12:171. [PMID: 24890327 DOI: 10.1186/1477-7819-12-171] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
80 Connor S, Neoptolemos JP. Laparoscopy is still necessary in the assessment of peri-ampullary neoplasia. Pancreatology 2004;4:415-6. [DOI: 10.1159/000079557] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
81 Schiergens TS, Renz BW, Reu S, Neumann J, Al-sayegh R, Nieß H, Ilmer M, Kruger S, Boeck S, Heinemann V, Werner J, Kleespies A. Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer. J Gastrointest Surg 2017;21:1775-83. [DOI: 10.1007/s11605-017-3489-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
82 Hinton J, Callan R, Bodine C, Glasgow W, Brower S, Jiang S, Li J. Potential epigenetic biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinomas. Expert Review of Molecular Diagnostics 2014;13:431-43. [DOI: 10.1586/erm.13.38] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
83 Kong D, Nishino N, Shibusawa M, Kusano M. Establishment and characterization of human pancreatic adenocarcinoma cell line in tissue culture and the nude mouse. Tissue and Cell 2007;39:217-23. [DOI: 10.1016/j.tice.2007.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
84 Tapper E, Kalb B, Martin DR, Kooby D, Adsay NV, Sarmiento JM. Staging laparoscopy for proximal pancreatic cancer in a magnetic resonance imaging-driven practice: what's it worth? HPB (Oxford) 2011;13:732-7. [PMID: 21929674 DOI: 10.1111/j.1477-2574.2011.00366.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
85 Liu X, Yang X, Zhou G, Chen Y, Li C, Wang X. Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma. Medicine (Baltimore) 2016;95:e3098. [PMID: 26986149 DOI: 10.1097/MD.0000000000003098] [Reference Citation Analysis]
86 Karachristos A, Scarmeas N, Hoffman JP. CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg. 2005;9:1286-1292. [PMID: 16332484 DOI: 10.1016/j.gassur.2005.06.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 4.2] [Reference Citation Analysis]
87 Halloran CM, Ghaneh P, Connor S, Sutton R, Neoptolemos JP, Raraty MG. Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy. Br J Surg 2008;95:453-9. [PMID: 18161888 DOI: 10.1002/bjs.6043] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
88 Agrawal S. Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma. World J Clin Oncol 2017; 8(3): 255-260 [PMID: 28638795 DOI: 10.5306/wjco.v8.i3.255] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
89 Liu X, Yang X, Zhou G, Chen Y, Li C, Wang X. Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma. Medicine (Baltimore) 2016;95:e3098. [PMID: 26986149 DOI: 10.1097/MD.0000000000003098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
90 Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG. Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era? J Am Coll Surg. 2009;208:87-95. [PMID: 19228509 DOI: 10.1016/j.jamcollsurg.2008.10.014] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 5.0] [Reference Citation Analysis]
91 Yovino S, Darwin P, Daly B, Garofalo M, Moesinger R. Predicting unresectability in pancreatic cancer patients: the additive effects of CT and endoscopic ultrasound. J Gastrointest Surg. 2007;11:36-42. [PMID: 17390184 DOI: 10.1007/s11605-007-0110-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
92 Diab HMH, Smith HG, Jensen KK, Jørgensen LN. The current role of blood-based biomarkers in surgical decision-making in patients with localised pancreatic cancer: A systematic review. Eur J Cancer 2021;154:73-81. [PMID: 34243080 DOI: 10.1016/j.ejca.2021.05.033] [Reference Citation Analysis]
93 Barton JG, Bois JP, Sarr MG, Wood CM, Qin R, Thomsen KM, Kendrick ML, Farnell MB. Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma. J Gastrointest Surg 2009;13:2050-8. [DOI: 10.1007/s11605-009-0849-z] [Cited by in Crossref: 61] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
94 Smith RA, Ghaneh P, Sutton R, Raraty M, Campbell F, Neoptolemos JP. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg 2008;12:1422-8. [PMID: 18543046 DOI: 10.1007/s11605-008-0554-3] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 6.1] [Reference Citation Analysis]
95 Scarà S, Bottoni P, Scatena R. CA 19-9: Biochemical and Clinical Aspects. Adv Exp Med Biol 2015;867:247-60. [PMID: 26530370 DOI: 10.1007/978-94-017-7215-0_15] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 16.5] [Reference Citation Analysis]
96 Raut CP, Evans DB, Crane CH, Pisters PW, Wolff RA. Neoadjuvant therapy for resectable pancreatic cancer. Surg Oncol Clin N Am 2004;13:639-61, ix. [PMID: 15350939 DOI: 10.1016/j.soc.2004.06.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
97 Rammohan A, Cherukuri SD, Palaniappan R, Perumal SK, Sathyanesan J, Govindan M. Preoperative Platelet–Lymphocyte Ratio Augments CA 19-9 as a Predictor of Malignancy in Chronic Calcific Pancreatitis. World J Surg 2015;39:2323-8. [DOI: 10.1007/s00268-015-3087-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
98 Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, Kim BR. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res. 2007;140:31-35. [PMID: 17418869 DOI: 10.1016/j.jss.2006.10.007] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 4.9] [Reference Citation Analysis]
99 Lee BS, Lee SH, Son JH, Jang DK, Chung KH, Paik WH, Ryu JK, Kim YT. Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma. J Gastroenterol Hepatol 2016;31:493-500. [PMID: 26220764 DOI: 10.1111/jgh.13059] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
100 Lee SY, Lee JH, Hwang DW, Kim SC, Park KM, Lee YJ. Long-term outcomes in patients with duodenal adenocarcinoma. ANZ J Surg 2014;84:970-5. [PMID: 23656271 DOI: 10.1111/ans.12112] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
101 Kim YC, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Shin JH. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? J Gastroenterol Hepatol. 2009;24:1869-1875. [PMID: 19686409 DOI: 10.1111/j.1440-1746.2009.05935.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 4.3] [Reference Citation Analysis]
102 Kondo N, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Nakashima A, Sakabe R, Shigemoto N, Kato Y, Ohge H, Sueda T. Prognostic impact of perioperative serum CA 19-9 Levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2010;17:2321-2329. [PMID: 20336387 DOI: 10.1245/s10434-010-1033-0] [Cited by in Crossref: 104] [Cited by in F6Publishing: 99] [Article Influence: 8.7] [Reference Citation Analysis]
103 Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17:1794-1801. [PMID: 20162463 DOI: 10.1245/s10434-010-0943-1] [Cited by in Crossref: 98] [Cited by in F6Publishing: 96] [Article Influence: 8.2] [Reference Citation Analysis]
104 Agrawal S, Gupta A, Gupta S, Goyal B, Siddeek RAT, Rajput D, Chauhan U, Kishore S, Gupta M, Kant R. Role of carbohydrate antigen 19-9, carcinoembryonic antigen, and carbohydrate antigen 125 as the predictors of resectability and survival in the patients of Carcinoma Gall Bladder. J Carcinog 2020;19:4. [PMID: 33033460 DOI: 10.4103/jcar.JCar_10_20] [Reference Citation Analysis]
105 Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, Büchler MW, Werner J. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20:2188-2196. [PMID: 23247983 DOI: 10.1245/s10434-012-2809-1] [Cited by in Crossref: 146] [Cited by in F6Publishing: 133] [Article Influence: 14.6] [Reference Citation Analysis]
106 La Torre M, Nigri G, Lo Conte A, Mazzuca F, Tierno SM, Salaj A, Marchetti P, Ziparo V, Ramacciato G. Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection? Gut Liver 2014;8:102-8. [PMID: 24516708 DOI: 10.5009/gnl.2014.8.1.102] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
107 van Manen L, Groen JV, Putter H, Vahrmeijer AL, Swijnenburg RJ, Bonsing BA, Mieog JSD. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis. Biomarkers. 2020;25:186-193. [PMID: 32009482 DOI: 10.1080/1354750x.2020.1725786] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
108 Moral A, Magarzo J. Marcadores tumorales serológicos en cirugía hepatobiliopancreática. Cirugía Española 2004;76:276-83. [DOI: 10.1016/s0009-739x(04)72378-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Watanabe F, Suzuki K, Tamaki S, Abe I, Endo Y, Takayama Y, Ishikawa H, Kakizawa N, Saito M, Futsuhara K, Noda H, Konishi F, Rikiyama T. Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients. Sci Rep 2021;11:20797. [PMID: 34675229 DOI: 10.1038/s41598-021-00060-9] [Reference Citation Analysis]
110 Kondo N, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Sasaki H, Sueda T. Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma. J Surg Oncol. 2014;110:422-429. [PMID: 24889968 DOI: 10.1002/jso.23666] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]